Unit:
Κατεύθυνση Οικονομία και Διοίκηση Υπηρεσιών ΥγείαςLibrary of the Faculty of Economics and of the Faculty of Business Administration
Supervisors info:
Ιωάννης Υφαντόπουλος Ομότιμος Καθηγητής, Τμήμα Πολιτικής Επιστήμης, ΕΚΠΑ
Original Title:
Μελέτη της αγοράς γενοσήμων στην Ελλάδα, Ιταλία, Ισπανία και Πορτογαλία από το 2013 και προτάσεις άρσης των εμποδίων διείσδυσής τους μέσω ΑΤΥ των αναφερομένων χωρών και των Ευρωπαϊκών κανόνων ανταγωνισμού
Translated title:
Study of generics market in Greece, Italy, Spain and Portugal since 2013 and proposals to remove barriers through HTA of the countries mentioned and European Competition Rules
Summary:
This paper addresses the penetration of generic pharmaceuticals in the pharmaceutical markets of Greece, Italy, Spain and Portugal from 2013 onwards, namely their pricing policy and their distribution on the pharmaceutical market of the countries under study. In addition, through the analysis of the characteristics of the drug category under consideration and the implementation of health technology assessment and European competition rules, specific pharmaceutical policy measures are proposed to effectively address the needs of the citizens of these countries in the light of economic viability of their health systems.
Searching for articles, publications and data from GOOGLE, GOOGLE SCHOLAR, the websites of the National Printing Works, the EOF and the Swedish Health Technology Assessment Body (TLV), the European Union (Access to Justice), and data from the OECD, SFEE, , ICAP on health expenditure on health expenditure and generic medicines in the countries under study in order to link the fluctuation of these costs with the change in the distribution of the category of drugs in question over time v These pharmaceutical markets.
Using the above methodology, the variation in the volume, value and price of the generic drugs in the studied countries was plotted and the low penetration of the latter in our country was documented (despite the gradual reduction of the compensation price) compared to the countries of the European South while, while referring to the health technology assessment bodies of these countries, cases of institutional European bodies have been reported on incidents that call into question the observance of of the principles of commercial competition in the generic medicines market
Extensive use of genes may positively affect the national economies of the countries under study, with moderation in spending, and this requires structural policy measures (especially for Greece, where the proportion of originals and generic medicines is found to be unfavorable in terms of last, implementation of the objectives of health technology assessment bodies and constant vigilance of European competition authorities
Main subject category:
Health Sciences
Keywords:
generics, categories of drugs, health systems, pharmaceutical policy in the European South, health technology, health technology assessment in Greece, international health technology assessment, health systems, European competition law, antitrust law
